Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and identifying a 60 mg once-daily dose to support planned registrational studies.
The study evaluated dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer.
Exposure Analysis Demonstrates High Response Rates
Preliminary efficacy results across 26 evaluable patients revealed an overall response rate of 86% among participants achieving target exposure levels above the specified threshold, compared to 58% for those below it.
This exposure-response relationship was clearest in patients with multiple marker lesions, supporting the 60 mg daily dosage for adjuvant settings with minimal disease burden.
